04-26-67

Express Mail Label No.: EV942366801US

Date of Deposit April 18, 2007

Attorney Docket No: 24852-501 CIP5 NATL

APR 1-8 2007

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Bacopoulos et al.

CONF. NO.::

5498

SERIAL NO.:

10/567,952

EXAMINER:

James D. Anderson

FILED:

February 10, 2006

ART UNIT:

1614

For:

METHODS OF TREATING CANCER WITH HDAC INHIBITORS

MAIL STOP AMENDMENT

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following:

- 1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (1 page), in duplicate;
- 3. Cited References A35; B17; C141; and
- 4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24852-501 CIP5 NATL. Please address all correspondence to Customer No. 35437. A duplicate copy of this Transmittal Letter is enclosed herewith.

Respectfully submitted,

Dated: April 18, 2007

Ivor Elrifi, Reg. No. 39,529

Michelle A. Iwamoto, Reg. No. 55,296

Attorneys for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS, et al.

666 Third Avenue, 24th Floor New York, New York 10017

Phone: (212) 935-3000 Fax: (212) 983-3115

Attorney Docket No: 24852-501 CIP5 NATL

Express Mail Label No.: EV942366801US
Date of Deposit: April 18, 2007
APR 1.8 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FLICANTS:

Bacopoulos et al.

CONF. NO.::

5498

SERIAL NO.:

10/567,952

EXAMINER:

James D. Anderson

FILED:

February 10, 2006

ART UNIT:

1614

For:

METHODS OF TREATING CANCER WITH HDAC INHIBITORS

MAIL STOP AMENDMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby makes of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. In accordance with MPEP §609(III)(A)(2), a copy of the cited U.S. publication is not required.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-identified application. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed modified Form PTO-1449 with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

Applicants: Bacopoulos et al. Attorney Docket No: 24852-501 CIP5 NATL

U.S.S.N.: 10/567,952

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by

35 U.S.C. §102.

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24852-501 CIP5 NATL, Customer No. 35437.

Respectfully submitted,

Dated: April 18, 2007

muchelle & Swams

Ivor Elrifi, Reg. No. 39,529 Michelle A. Iwamoto, Reg. No. 55,296 Attorneys for Applicants c/o MINTZ, LEVIN, COHN, FERRIS GLOVSKY & POPEO P.C. Chrysler Center 666 Third Avenue, 24th Floor

New York, New York 10017 Phone: (212) 935-3000

Fax: (212) 983-3115

2

Express Mail Label No.: EV942366801US Date of Deposit: April 18, 2007

(+) in this box



PTO/SB (12-97) OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/567,952
Filing Date	February 10, 2006
First Named Inventor	Bacopoulos
Group Art Unit / Conf. No.:	1614 / 5498
Examiner Name	James D. Anderson
Attorney Docket Number	24852-501 CIP5 NATL

			U.S. PATENT DOCUMENTS				
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date	
	A35	2005/0004007	01/06/05	Grant et al.	514	7	03/05/2003

				FOREIGN PATENT DOCUMENTS			
Exam Cite Foreign Patent Document No. Office Number			Name of Patentee(s) or Applicant(s)	Date of Publication English Yes No		lish No	
	B17	EP .	0547000 A1	Kabadi .	June 16, 2003	Х	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Exam Cite Initials No. Name of Author, Title (when appropriate), P		Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.	
	C141	Rubartelli et al. (1995); "High Rates of Thioredoxin Secretion Correlate with Growth Arrest in Hepatoma Cells"; Cancer Research; Vol. 55, pages 675-680.	

*a copy of this	reference is not provided as it	was previously cited b	y or submitted to the	office in a prior application,
Serial No	, filed	, and relied upon fo	or an earlier filing date	e under 35 U.S.C. §120
(continuation.	continuation-in-part, and division	onal applications).		_

Examiner Signature		Date Considered	
			<u> </u>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.